{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T20:54:11Z","timestamp":1789419251669,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["875534"],"award-info":[{"award-number":["875534"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003286","name":"Kuwait Foundation for the Advancement of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003286","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004242","name":"Princess Nourah Bint Abdulrahman University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004242","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022690","name":"JDRF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022690","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005402","name":"Dasman Diabetes Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005402","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019787","name":"Sophia University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.diabres.2025.113066","type":"journal-article","created":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T15:33:57Z","timestamp":1766331237000},"page":"113066","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Combining glucagon-like peptide 1 analogues with sodium-glucose cotransporter 2 inhibitors to treat patients with type 1 diabetes, BMI &gt; 25\u00a0kg\/m2, and chronic kidney disease \u2013 A randomised, controlled pilot study"],"prefix":"10.1016","volume":"231","author":[{"given":"Ebaa","family":"Al Ozairi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etab","family":"Taghadom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7520-0221","authenticated-orcid":false,"given":"Mohammad","family":"Irshad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas Al","family":"Yousef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jumana","family":"AlKandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0020-4391","authenticated-orcid":false,"given":"Werd","family":"Al-Najim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahd","family":"Alabdulkader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander D","family":"Miras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carel W.","family":"le Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.diabres.2025.113066_b0005","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/MED.0000000000000074","article-title":"Early diabetic nephropathy in type 1 diabetes: new insights","volume":"21","author":"Bjornstad","year":"2014","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"11","key":"10.1016\/j.diabres.2025.113066_b0010","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1007\/s00125-022-05778-3","article-title":"Precision medicine in type 1 diabetes","volume":"65","author":"Carr","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2025.113066_b0015","article-title":"11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes\u20142024","volume":"47(Supplement_1):S219\u2013S230","author":"Committee","year":"2023","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.diabres.2025.113066_b0020","doi-asserted-by":"crossref","first-page":"582","DOI":"10.7326\/M22-3051","article-title":"Recommended and Prevalent use of Glucagon-like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors in a National Population-Based Sample","volume":"176","author":"Tang","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabres.2025.113066_b0025","doi-asserted-by":"crossref","DOI":"10.1161\/circ.148.suppl_1.17437","article-title":"Estimated Lifetime Cardiovascular, Kidney and Mortality Benefits of Combination Treatment with SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Non-steroidal MRA Compared with conventional Care in Patients with Type 2 Diabetes and Albuminuria","author":"Neuen","year":"2023","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.diabres.2025.113066_b0030","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/dom.15287","article-title":"Albuminuria-lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: a randomized and placebo-controlled study","volume":"26","author":"Sivalingam","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2025.113066_b0035","doi-asserted-by":"crossref","DOI":"10.1007\/s00125-023-05975-8","article-title":"SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study","author":"Anson","year":"2023","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.diabres.2025.113066_b0040","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2337\/dc21-1584","article-title":"Real-world evidence of Efficacy and Safety of SGLT2 Inhibitors as Adjunctive Therapy in adults with Type 1 Diabetes: a European Two-Center Experience","volume":"45","author":"Palanca","year":"2022","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.diabres.2025.113066_b0045","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/dom.13911","article-title":"Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: the Lira Pump trial\u2014a randomized, double-blinded, placebo-controlled trial","volume":"22","author":"Dejgaard","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.diabres.2025.113066_b0050","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12933-020-01154-w","article-title":"Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes","volume":"19","author":"Schernthaner","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabres.2025.113066_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101510","article-title":"Kidney outcomes associated with sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists: a real-world population-based analysis","volume":"50","author":"Lui","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"12","key":"10.1016\/j.diabres.2025.113066_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2023.108632","article-title":"The effect of sodium-glucose cotransporter 2 inhibitors as an adjunct to insulin in patients with type 1 diabetes assessed by continuous glucose monitoring: a systematic review and meta-analysis","volume":"37","author":"Li","year":"2023","journal-title":"J Diabetes Complications"},{"issue":"12","key":"10.1016\/j.diabres.2025.113066_b0065","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1111\/dom.14160","article-title":"Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: results of the LEADER and SUSTAIN 6 trials","volume":"22","author":"Verma","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.diabres.2025.113066_b0070","doi-asserted-by":"crossref","first-page":"13009","DOI":"10.1038\/s41598-019-49525-y","article-title":"Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in patients with Type 2 Diabetes: a Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"9","author":"Bae","year":"2019","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.diabres.2025.113066_b0075","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12933-019-0852-y","article-title":"Effect of SGLT2 inhibitors on body composition, fluid status and renin\u2013angiotensin\u2013aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy","volume":"18","author":"Schork","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabres.2025.113066_b0080","doi-asserted-by":"crossref","unstructured":"Al-Ozairi E., Narula K., Miras A.D., et al. Obesity Treatments to Improve Type 1 Diabetes (OTID): a randomized controlled trial of the combination of glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 inhibitors-protocol for Obesity Treatments to Improve Type 1 Diabetes (the OTID trial). Trials 2024;25(1):129. https:\/\/doi: 10.1186\/s13063-024-07930-3.","DOI":"10.1186\/s13063-024-07930-3"},{"key":"10.1016\/j.diabres.2025.113066_b0085","doi-asserted-by":"crossref","unstructured":"Alkandari J., Taghadom E., Irshad M., et al. Impact of Dose Adjustment for Normal Eating courses on glycemic control, severe hypoglycemia, and diabetic ketoacidosis in people with type 1 diabetes. Diabetes 2025; 74 (Supplement_1): 519-P. https:\/\/doi.org\/10.2337\/db25-519-P.","DOI":"10.2337\/db25-519-P"},{"issue":"3","key":"10.1016\/j.diabres.2025.113066_b0090","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(15)00436-2","article-title":"Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial","volume":"4","author":"Dejgaard","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"Supplement_1","key":"10.1016\/j.diabres.2025.113066_b0095","doi-asserted-by":"crossref","DOI":"10.2337\/db22-751-P","article-title":"751-P: effect of Once-Weekly Semaglutide on Weight Change and Metabolic Control in people with Type 1 Diabetes\u2014Six-months results from the Real-World STEMT Trial","volume":"71","author":"Mertens","year":"2022","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.diabres.2025.113066_b0100","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2337\/dc18-0623","article-title":"Efficacy and Safety of Dapagliflozin in patients with Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week results from a Randomized Controlled Trial","volume":"41","author":"Mathieu","year":"2018","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.diabres.2025.113066_b0105","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/oby.23677","article-title":"Glucagon\u2010like peptide\u20101 agonists combined with sodium\u2010glucose cotransporter\u20102 inhibitors reduce weight in type 1 diabetes","volume":"31","author":"Al-Ozairi","year":"2023","journal-title":"Obesity"},{"issue":"5","key":"10.1016\/j.diabres.2025.113066_b0110","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2337\/dc20-2839","article-title":"Cardiovascular and Renal Disease Burden in Type 1 Compared with Type 2 Diabetes: a Two-Country Nationwide Observational Study","volume":"44","author":"Krist\u00f3fi","year":"2021","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.diabres.2025.113066_b0115","doi-asserted-by":"crossref","first-page":"329","DOI":"10.4330\/wjc.v14.i6.329","article-title":"Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes","volume":"14","author":"Singh","year":"2022","journal-title":"World J Cardiol"},{"issue":"4","key":"10.1016\/j.diabres.2025.113066_b0120","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2337\/dc21-1113","article-title":"Primary Prevention of Cardiovascular and Heart failure events with SGLT2 Inhibitors, GLP-1 Receptor Agonists, and their Combination in Type 2 Diabetes","volume":"45","author":"Wright","year":"2022","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.diabres.2025.113066_b0125","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","volume":"4","author":"Fr\u00edas","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.diabres.2025.113066_b0130","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.diabres.2025.113066_b0135","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725010812?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725010812?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T14:21:04Z","timestamp":1769696464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822725010812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":27,"alternative-id":["S0168822725010812"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2025.113066","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combining glucagon-like peptide 1 analogues with sodium-glucose cotransporter 2 inhibitors to treat patients with type 1 diabetes, BMI > 25\u00a0kg\/m2, and chronic kidney disease \u2013 A randomised, controlled pilot study","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2025.113066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113066"}}